Publication: Effect of smartphone-assisted lifestyle intervention in MASLD patients: a randomized controlled trial
0
0
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85196099069
Pubmed ID
38886203
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Kaewdech A., Assawasuwannakit S., Churuangsuk C., Chamroonkul N., Sripongpun P. Effect of smartphone-assisted lifestyle intervention in MASLD patients: a randomized controlled trial. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-64988-4 Retrieved from: https://hdl.handle.net/20.500.14740/20769
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging globally as a significant problem. The mainstay of treatment is lifestyle intervention (LSI). We hypothesized that providing information regarding LSI and MASLD through a social media application generally used in the respective society would improve clinical outcomes in MASLD more than standard of care (SOC). This is a randomized controlled study in noncirrhotic MASLD patients aged 18–65 years in Thailand. Eligible patients were randomly assigned to either the control (SOC) or intervention arm. Patients in both groups received standard LSI advice. Infographics about MASLD and LSI information were sent to the intervention group every 3–7 days via the LINE official account. The outcomes are changes in liver steatosis and liver stiffness by FIBROSCAN at 24 weeks, as well as weight loss, body composition, and serum alanine aminotransferase (ALT) level between the two groups. A total of 122 patients were enrolled. The median age of eligible participants was 53 years, 64.7% were female, and median body mass index was 27.3 kg/m2. After a complete 24-week study period, both groups had an improvement in weight, ALT level, liver steatosis, and fat mass, but the differences in those changes between groups were not statistically significant. Interestingly, a significant improvement in liver stiffness was observed in the intervention group than in the control group (− 0.7 ± 1.8 kPa vs. 0.1 ± 2.4 kPa, P = 0.035). Encouraging LSI and delivering MASLD information via a social media application (LINE official account) to patients with MASLD demonstrated a better outcome of liver stiffness measurement than SOC. Clinical trial number: TCTR20210304002 (04/03/2021) (http://www.thaiclinicaltrials.org/show/TCTR20210304002).